BDBM439578 US10633345, Compound 257b::US10689346, Compound 257b::US11203574, Compound 257b::US11230530, Compound 257b::US11685721, Compound 257b::US11708332, Compound 257b

SMILES Nc1nccc2ccc(cc12)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1cccc(c1)C#N)C(F)(F)F

InChI Key InChIKey=PQPAZBKFVDKERF-UHFFFAOYSA-N

Data  7 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 439578   

TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM439578(US10633345, Compound 257b | US10689346, Compound 2...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM439578(US10633345, Compound 257b | US10689346, Compound 2...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM439578(US10633345, Compound 257b | US10689346, Compound 2...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM439578(US10633345, Compound 257b | US10689346, Compound 2...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM439578(US10633345, Compound 257b | US10689346, Compound 2...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM439578(US10633345, Compound 257b | US10689346, Compound 2...)
Affinity DataKi:  25.1nMAssay Description:Plasma kallikrein activity assay. The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM439578(US10633345, Compound 257b | US10689346, Compound 2...)
Affinity DataKi:  25.1nMAssay Description:Plasma kallikrein activity assay. The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent